Background/Aims: To determine which drug-eluting stents are more effective in acute myocardial infarction (MI) patients with chronic kidney disease (CKD). Methods: This study included a total of 3,566 acute MI survivors with CKD from the Korea Acute Myocardial Infarction Registry who were treated with stenting and followed up for 12 months: 1,845 patients who received sirolimus-eluting stents (SES), 1,356 who received paclitaxel-eluting stents (PES), and 365 who received zotarolimus-eluting stents (ZES). CKD was defined as an estimated glomerular filtration rate < 60 mL/min/1.73 m 2 calculated by the modification of diet in renal disease method. Results: At the 12-month follow-up, patients receiving ZES demonstrated a higher incidence (14.8%) of major adverse cardiac events (MACEs) compared to those receiving SES (10.1%) and PES (12%, p = 0.019). The ZES patients also had a higher incidence (3.9%) of target lesion revascularization (TLR) compared to those receiving SES (1.5%) and PES (2.4%, p = 0.011). After adjusting for confounding factors, ZES was associated with a higher incidence of MACE and TLR than SES (adjusted hazard ratio [HR], 0.623; 95% confidence interval [CI], 0.442 to 0.879; p = 0.007; adjusted HR, 0.350; 95% CI, 0.165 to 0.743; p = 0.006, respectively), and with a higher rate of TLR than PES (adjusted HR, 0.471; 95% CI, 0.223 to 0.997; p = 0.049). Conclusions: Our findings suggest that ZES is less effective than SES and PES in terms of 12-month TLR, and has a higher incidence of MACE due to a higher TLR rate compared with SES, in acute MI patients with CKD.
INTRODUCTION

Primary percutaneous coronary intervention (PCI)
with stent implantation is considered the standard treatment strategy in patients with acute myocardial infarction (MI) [1] . Compared with bare-metal stents (BMS), drug-eluting stents (DES) decrease late luminal loss and angiographic restenosis by reducing neointimal hyperplasia. Although recent studies have demonstrated that use of DES in acute MI is safe and effective [2] [3] [4] , vessel healing at the primary pathological site in patients treated with DES for acute MI is delayed compared with in patients receiving DES for stable angina [5] . However, second-generation DES, such as zotarolimus-eluting stent (ZES), may improve vessel healing and endothelial function as well as biologic compatibility [6] [7] [8] .
Chronic kidney disease (CKD) patients are known to be at high risk of developing coronary artery disease, and CKD is significantly associated with increased mortality, MI, and restenosis [9, 10] . In these patients, DES has also been shown to be superior to BMS in terms of reduction of clinical and angiographic restenosis [11, 12] .
There have been many comparative studies of DES [13] [14] [15] , but little data are available on the relative effectiveness of particular DES in acute MI patients with CKD.
This issue has important implications for the selection of the most effective treatment strategy in these highrisk patients. Hence, the objective of this study was to determine which DES are more effective in acute MI patients with CKD.
METHODS
Korea Acute Myocardial Infarction Registry (KAMIR)
The KAMIR is a prospective multicenter online registry designed to describe the characteristics and clinical outcomes of Korean patients with acute MI and reflect current patient management practice. The registry included 52 community and university hospitals capable of primary PCI, and data on 13,133 patients with a 12-month clinical follow-up at the time of this study [16] .
Data were collected at each site by an experienced study coordinator based on a standardized protocol. The study protocol was approved by the ethics committee of each participating institution. 
Study population
Definitions and clinical endpoints
Renal function was assessed by eGFR, calculated using the MDRD method [17] , based on the serum cre- flow grade [19] .
Clinical follow-up was performed at 12 months after the commencement of the study. Major adverse cardiac events (MACE) included all-cause death, MI, and target lesion revascularization (TLR). TLR was defined as a repeat stent implantation at the initial site or within 5 mm proximal or distal to the stent [3] .
Statistical analysis
All analyses were performed using SPSS version 17 Values are presented as mean ± SD or number (%).
SES, sirolimus-eluting stent; PES, paclitaxel-eluting stent; ZES, zotarolimus-eluting stent; BMI, body mass index; CAD, coronary artery disease; HF, heart failure; EF, ejection fraction; eGFR, estimated glomerular filtration rate; GP, glycoprotein; ACE-I, angiotensinconverting enzyme inhibitor; ARB, angiotensin II receptor blocker. a Medication at discharge. 
RESULTS
Baseline clinical and procedural characteristics
A comparison of the clinical characteristics among the three DES groups suggested that age was greater in the PES group, BMI was higher and usage rate of GP IIb/IIIa inhibitor during the procedure lower in the SES group, and usage rate of cilostazol was lower in the ZES group (Table 1) . A comparison of the procedural characteristics demonstrated that the incidence of LM complex lesion and multivessel disease were higher and the total number of stents was greater in the PES group.
Stent length was longer, stent diameter was smaller, and achievement rate of post-procedural TIMI 3 flow was lower in the SES group. The incidence of complex lesions was also higher in the ZES group (Table 2) .
Twelve-month clinical outcomes
The cumulative MACE rate after 12 months was significantly higher in the ZES group than in the SES group (SES, 10.1%; PES, 12.0%; ZES, 14.8%; p = 0.019). 
Multivariate analysis
In the multivariate analysis, diabetes mellitus, LM complex lesion, multivessel disease, eGFR < 30 mL/ min/1.73 m 2 , and STEMI and use of ZES were identified as independent predictors of 12-month MACE (Table  3 ). In contrast, independent predictors of death after 12 months or MI were age ≥ 65 years, BMI, LM complex lesion, and eGFR < 30 mL/min/1.73 m 2 ( Table 4 ). The independent predictors of 12-month TLR included use of ZES (Table 5 ). Adjusted survival curves are shown in Fig. 2 . The ZES group was associated with a higher incidence of MACE (adjusted HR, 0.623; 95% CI, 0.442 to 0.879; p = 0.007) and TLR than the SES group (adjusted HR, 0.350; 95% CI, 0.165 to 0.743; p = 0.006). In addition, being in the ZES group was associated with a higher incidence of TLR than in the PES group (adjusted HR for TLR, 0.471; 95% CI, 0.223 to 0.997; p = 0.049).
DISCUSSION
This study was designed to compare the 12-month clinical outcomes among ZES, SES, and PES in acute MI patients with CKD. Multivariate analyses and Cox regression models showed that ZES was associated with a higher incidence of MACE than SES, and a higher rate of TLR than SES and PES.
In patients with acute MI, primary PCI with stent implantation is considered to be the gold standard in treatment for acute MI [1] . Although PCI with stent implantation is performed in increasing numbers of patients, in-stent restenosis is an important complication.
Studies of patients with acute MI treated with BMS have reported the incidence of repeated revascularization to be about 10% [2, 3] . Most suggested that DES was associated with a lower restenosis and TLR rate compared with BMS [2] [3] [4] . The data reported here support the use of DES in acute MI since the TLR rate for all types of DES was 2.1%.
CKD patients are known to be a high-risk population for coronary artery disease. Cardiovascular events, especially related to coronary artery disease, remain the main cause of mortality among patients with CKD [9, 10] . Furthermore, the presence of CKD increases the risk of mortality after PCI even before end-stage renal disease and dialysis dependency have developed [20] .
In support of this, an eGFR < 30 mL/min/1.73 m 2 in the current study was a significant independent predictor of MACE, MI, or death after 12 months.
A concern following DES implantation in acute MI patients is that vessel healing at the primary pathological site is delayed compared with in stable angina patients, which results in an increased risk of thrombotic complications [5] . ZES, which is second-generation DES and is based on a different type of polymer, is closer to BMS than first-generation DES. ZES implantation is associated with less inflammation and greater endothelialization [8] , and preserved endothelial vasomotor response 
Limitations
This is the first study based on observational registry data. We used Cox regression analysis to correct for A C B [24, 25] . Unfortunately, in this registry, data concerning the rates of stent thrombosis were not available. As a consequence, it was not possible to assess one of the most important safety markers. Finally, we compared both first-and second-generation DES. However, the ZES in this study was not the Endeavor Resolute Stent (Medtronic Vascular) but the Endeavor Sprint Stent (Medtronic Vascular). Since some studies have already demonstrated that new-generation DES might be safer and more effective than earlier-generation types, further evaluations of new-generation DES are urgently needed.
In conclusion, our data suggest that ZES is inferior to SES and PES in terms of 12-month TLR, and has a higher incidence of MACE. The latter is due mainly to the higher TLR rate compared with SES in acute MI patients with CKD.
